Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

The Software Experts analysis reflects a broader trend in creative software toward tools that bridge online accessibility and production readiness. As design output increasingly moves from screen to ...

The hyper-intensified process delivers significant increases in AAV yield and full capsid percentage through a novel adherent, perfusion-based manufacturing approach PHILADELPHIA, May 15, ...

The use of viral vectors as gene delivery and vaccine vehicles has developed rapidly during the last two decades owing to several viral properties. Viruses can infect cells efficiently, often have a ...

Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...

We previously published a report on the scale-up and manufacturing of clinical-grade SIN gRV vectors by transient transfection in a closed-system bioreactor in which we identified optimized ...

Regulatory requirements stipulate that the production of any agents intended for use in human clinical trials must be performed under current Good Manufacturing Practices (cGMP). 1 Retroviral vector ...